By Salong Debbarma
Publication Date: 2026-08-19 10:30:00
US-based biotechnology company Abcuro has closed a $66m Series D funding round to support its new clinical trial of ulviprubart for inclusion body myositis (IBM).
The company’s potential registrational study will evaluate the monoclonal antibody in patients with less severe IBM, with trial initiation targeted for the final quarter of 2026.
Ulviprubart targets killer cell lectin-like receptor G1 (KLRG1) on cytotoxic T cells.
Abcuro expects top line results in the second half of 2028.
The investment round was led by New Leaf Venture Partners and joined by participants that include Bain Capital Life Sciences,Eurofarma Ventures, Foresite Capital, Kaitai Capital, Mass General Brigham Ventures, Pontifax, RA Capital Management, and Redmile Group.
In addition, Samsara BioCapital, Sanofi Ventures, Shang Bay, Soleus Capital, and new investor Rock Springs Capital participated in the round.
The company has already started…